Visit the Procter Machinery Guarding web site
Click on the advert above to visit the company web site

Product category: Engineering Industry Reports and Surveys
News Release from: ARC Advisory Group
Edited by the Engineeringtalk Editorial Team on 06 April 2006

Reports sees evolution in
pharmaceuticals

Request your FREE weekly copy of the Engineeringtalk email newsletter. News about Engineering Industry Reports and Surveys and more every issue. Click here for details.

Report says because of limited capital, equipment and talented human assets, increasing asset use and return on assets is vital to future success and survival for pharmaceutical manufacturing.

Pharmaceutical manufacturing is evolving from a high margin, large volume, make-to-stock, supply-driven operation to a price sensitive, small volume, flexible, make-to-order, personalised, value-driven services operation, according to a report With limited available capital, equipment and talented human assets, increasing asset use and return on assets is becoming vital to future success and survival

Companies are building manufacturing cultures that foster innovation and teamwork while using common tools, technologies and standards that deliver added value and financial benefit to their businesses.

"The pharmaceutical industry is in rapid transition from a supply-driven market to a demand- and service-driven market where manufacturing efficiency and responsiveness will play a critical role in future success", said Asish Ghosh, author of ARC's Pharmaceutical Industry Automation Worldwide Outlook.

Leading suppliers are keenly aware of the quickening pace of IT adoption in the building automation systems (BAS) market and are working hard to expand strategic differentiators to improve competitive advantage over peers.

ARC expects BAS to expand in functionality to fit a broader range of applications from the largest enterprises to more focused methods that can grow in functionality as companies increase investments.

Regulatory requirements in the life sciences and food markets are fuelling significant investments in integrated BAS products.

Companies in the life sciences industries are realising the importance of integrated BAS to meet the requirements of 21 CFR Part 11, the electronic-recordkeeping requirements imposed by the Food and Drug Association in the USA.

Integrated BAS products significantly reduce the cost and time to achieving and maintaining regulatory compliance for manufacturers in the life sciences market.

Key areas of cost savings include reduced project engineering, training, documentation and maintenance costs.

Current manufacturing, regulatory and technology deployment activities are placing additional emphasis on patient safety.

However, the growth of counterfeit and grey market drugs, the recent exposure of a limited drug manufacturing and delivery system capacity, increased regulatory and customer requirements, and an increased number of litigations continue to require deployment of additional technology that is affecting production, business operations and supply chain processes.

These deployments include product authentication, tracking and tracing with barcode and RFID technologies, anti-counterfeit measures in packaging, and product formulation.

ARC Advisory Group: contact details and other news
Email this article to a colleague
Register for the free Engineeringtalk email newsletter
Engineeringtalk Home Page

Search the Pro-Talk network of sites

Visit the Procter Machinery Guarding web site